National Institute for Health and Care Excellence (NICE) March 2016 - PMM supports clinical assessment recommendations in the NICE guidelines on suspected cancer, fever in under 5s and child maltreatment. It also supports the NICE technology appraisal guidance on abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis and tocilizumab for the treatment of systemic juvenile idiopathic arthritis.